DR. MARK PIMENTEL, M.D.
Osteopathic Medicine in Los Angeles, CA

2008013, Jun 12, 2008

Feb 13, 2008

12/030758

Mark Pimentel - Los Angeles CA, US
Henry C. Lin - Albuquerque NM, US

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

A61K 35/74

424 934

Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.

6805852, Oct 19, 2004

Mar 26, 2002

10/107240

Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

A61K 5100

424 111, 424 91, 435 4, 435 772, 435 34

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohns disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohns disease.

6562629, May 13, 2003

Aug 11, 1999

09/374143

Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

G01N 33564

436506, 435 4, 435 71

Disclosed is a method of diagnosing small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder (ADHD), or an autoimmune disease by sampling serum from a human subject having a suspected diagnosis of any of these conditions and analyzing the serum for the presence of ASCA, which corroborates the suspected diagnosis. A method of determining a predisposition for developing Crohns, in a human subject who does not present a set of symptoms characteristic of the disease and who has small intestinal bacterial overgrowth, involves sampling serum from the subject and analyzing the serum for the presence of ASCA. The presence of ASCA in the serum indicates a predisposition for developing Crohns disease. Also disclosed is a kit for diagnosing and treating small intestinal bacterial overgrowth, irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, or an autoimmune disease, such as multiple sclerosis or systemic lupus erythematosus.

7605240, Oct 20, 2009

Aug 14, 2007

11/838672

Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US

Cedara-Sinai Medical Center - Los Angeles CA

C07G 11/00

536 168

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.

2006024, Nov 2, 2006

May 20, 2003

10/514188

Mark Pimentel - Los Angeles CA, US
Henry Lin - Los Angeles CA, US

A61K 35/74, A61K 31/405

424093450, 514419000

Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject Also disclosed is the use, in the manufacture of a medicamens for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane, or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.

8388935, Mar 5, 2013

Dec 9, 2011

13/315671

Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A61K 49/00, A61K 35/00, A61K 45/00

424 92, 424 91, 424116, 4242781, 424439, 426 5, 426 71, 426658, 426800, 435 5, 435 29

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

7718608, May 18, 2010

Sep 19, 2008

12/234502

Henry C Lin - Manhattan Beach CA, US
Mark Pimentel - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A01N 37/18, A61K 39/00

514 2, 4241841

Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome.

8236760, Aug 7, 2012

Apr 24, 2008

12/597892

Mark Pimentel - Los Angeles CA, US
Edy E. Soffer - Los Angeles CA, US
Jeffrey Conklin - Los Angeles CA, US

Cedars-Sinsai Medical Center - Los Angeles CA

A61K 38/26, A61K 38/00

514 72, 514 117, 530300

The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.